Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question

Report Code: PHM212A

Publish Date: Jul 2019

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect.

This report will assess the latest developments in the IL-2 research and development and explore the novel strategies companies are adopting to augment immune response and avoid off target effects in a wide range of conditions including, metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), Type 1 diabetes (T1D), as a prophylaxis post-transplant and allergic conditions.

What's coming: There are more than 200 studies underway evaluating IL-2 based therapies either as a monotherapy or in combination. The key products and companies that we believe are worth watching in this space are summarized.

Report Includes

  • An introduction to interleukin-2 (IL-2) and identification of its applications
  • Insights into the latest trends and technologies in the IL-2 research and development
  • Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
  • Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent  CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing  a novel oncologic monoclonal antibody that boosts  IL-2 but has an improved side-effect profile
  • Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
  • An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)

Analyst Credentials

Dr. Cheryl Lee Barton has more than 10 years’ practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C.L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question17Free

Related Reports

Cancer Immunotherapy: Technologies and Global Markets

Published - Apr 2025 | Publisher - BCC Publishing | Code - PHM129C

The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.

Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy

Published - Aug 2019 | Publisher - Dr. Cheryl Lee Barton | Code - BIO129A

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

Colorectal Cancer Therapeutics: Global Markets

Published - Apr 2019 | Publisher - BCC Publishing | Code - PHM211A

The global colorectal cancer therapeutics market should reach $18.5 billion by 2023 from $13.7 billion in 2018 at a compound annual growth rate (CAGR) of 6.1% for the period 2018 to 2023.

Brain Tumor Therapeutics: Global Markets to 2023

Published - Jan 2019 | Publisher - BCC Publishing | Code - PHM208A

The global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% for the period of 2018-2023.

Recent Reports

Cancer Immunotherapy: Technologies and Global Markets

Published - Apr 2025 | Publisher - BCC Publishing | Code - PHM129C

The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.

Nanotechnology in Cancer Treatment: Technologies and Global Markets

Published - Apr 2025 | Publisher - BCC Publishing | Code - PHM222B

The report provides an analysis of the global market for nanotechnology in cancer treatment. Using 2023 as the base year, the report provides estimated market data for 2024 through 2029. The market in this report is segmented into product type, cancer type, and region. The report concludes with profiles of the major players in the market.

Radiopharmaceuticals: Technologies and Global Markets

Published - Apr 2025 | Publisher - BCC Publishing | Code - PHM171C

The global radiopharmaceuticals market is expected to grow from $10.3 billion in 2024 and is projected to reach $21.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 16.4% during the forecast period of 2024 to 2029.

Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

Published - Mar 2025 | Publisher - BCC Publishing | Code - PHM177C

The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.

Epigenetics: Technologies and Global Markets

Published - Mar 2025 | Publisher - BCC Publishing | Code - PHM044D

The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.

Top Trending Reports

Global Diabetic Care Devices Market

Published - Feb 2025 | Publisher - BCC Publishing | Code - MDS019B

The global market for diabetes monitoring devices is expected to grow from $16.6 billion in 2024 to $26.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.1% from 2024 through 2029.

Carbon Capture, Utilization & Storage Technologies

Published - Feb 2025 | Publisher - BCC Publishing | Code - EGY037G

The global market for carbon capture, utilization and storage (CCUS) technologies is expected to grow from $3.4 billion in 2024 and is projected to reach $9.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.1% during the forecast period of 2024 to 2029.

2024 Semiconductor Manufacturing Research Review

Published - Mar 2025 | Publisher - BCC Publishing | Code - SMC086G

This 2024 Research Review of the Semiconductor Manufacturing provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions.

Generative AI: Global Markets

Published - Jan 2025 | Publisher - BCC Publishing | Code - IFT308A

The global market for generative AI was valued at $15.4 billion in 2023. It is projected to grow from $20.8 billion in 2024 to $94.4 billion by 2029, at a compound annual growth rate (CAGR) of 35.3% from 2024 through 2029.

2024 Medical Devices Research Review

Published - Mar 2025 | Publisher - BCC Publishing | Code - MDS060B

The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question
Customize Report